ELISpot and FluoroSpot Assay Market Share, Size, Trends, Industry Analysis Report, By Product (Assay Kits, B Cell Assay, T Cell Assay, Ancillary Products, and Analyzers); By Application; By End-Use; By Region; Segment Forecast, 2024 - 2032
- Published Date:Jan-2024
- Pages: 114
- Format: PDF
- Report ID: PM3103
- Base Year: 2023
- Historical Data: 2019-2022
Report Outlook
The global elispot and fluorospot assay market was valued at USD 287.75 million in 2023 and is expected to grow at a CAGR of 6.6% during the forecast period. The continuously growing research activities of various vaccines across the globe to tackle the drug-resistant strains challenges effectively, the growing prevalence of chronic illness, and high technological advancements in ELISpot and FluoroSpot analyzers and assays kits as well are primary factors driving the growth of the global market.
Know more about this report: Request for sample pages
Moreover, rapidly growing awareness regarding the importance of early diagnosis of chronic diseases along with the rising healthcare spending especially in developing nations like India, China, and Indonesia are likely to fuel the market growth over the coming years.
According to the World Health organization, non-communicable diseases cause for over 41 million deaths every year, equivalent to 74% of all deaths globally. Cardiovascular disease account for the largest number of deaths globally with 17 million people annually. And, around 77% of all NCD deaths are in low and medium sized economies.
Increasing prevalence of this technology and gaining traction of these assay kits owing to its ability to measure wide range of immune response and cellular immune related activities coupled with the vast applications of ELISpot assays like IFN-gamma, Granzyme B ELISpot, and TGF-Beta are likely to create significant market growth opportunities.
However, the limited availability of the detection reagents used in several assay detection techniques & high sensitivity of array methods compared to others available in the market are some major factors expected to restrain the growth of the global market in the coming year. In addition, the easy presence of many other efficient and cost-effective technologies in the industry and lack of awareness regarding the use of this technology in low income countries is also hampering the market growth.
The outbreak of the COVID-19 pandemic has significantly impacted the growth of the market. The rapid emergence of deadly coronavirus has forced countries to impose lockdowns and other stringent regulations, that led to the reduction in the demand and revenue for majority of equipment use in the surgeries. Various types of surgical procedures were on hold or being avoided during the pandemic to get control on the spread on the disease.
Know more about this report: Request for sample pages
Industry Dynamics
Growth Drivers
The increased incidence of chronic diseases, rapid surge in the awareness for timely diagnosis and continuous implementation on the development of several types of assays coupled with the high potential among the emerging countries by investing heavily in the healthcare sector are primary factors fueling the global elispot and fluorospot assay market growth.
Moreover, growing proliferation of infectious diseases that could be easily diagnosed using ELISpot and FluoroSpot assay are also likely to impact the market positively over the coming years.
Furthermore, an extensive rise in the preference for cell-based assays in the drug discovery as key component in the drug development process as it comes with numerous advantages over vitro biochemical assays and offer consistent tissue-specific responses are further anticipated to create high market growth opportunities.
Report Segmentation
The market is primarily segmented based on product, application, end-use, and region.
|
By Product |
By Application |
By End-Use |
By Region |
|
|
|
|
Know more about this report: Request for sample pages
T-Cell Assay Segment is Projected to Witness Fastest Growth over the Forecast Period
The t-cell assay segment is expected to grow at a high CAGR during the anticipated period due to the growing incidence of cancer and high growth in the research & development-based activities coupled with the expanding manufacturing capabilities and increasing approvals around the world. Moreover, a rapid increase in the geriatric population and growing number of lymphoma and leukemia cases worldwide are expected to significantly augment the segment growth.
According to the Leukemia and Lymphoma Society, a total of 186,000 people is estimated to be diagnosed with the leukemia, lymphoma, and myeloma in the Unites States in 2021. Approximately every 3 minutes, one person is diagnoses with these diseases in the US and about every 9 minutes, someone dies from the blood cancer in the country.
Diagnostics Segment Accounted for the Largest Market Share in 2022
Increased focus by key market players of the healthcare sectors towards the adoption of advanced technologies including artificial intelligence and machine learning to manufacturer efficient diagnostics systems along with the miniaturization in the chip technology are key factors propelling the segment market growth.
Furthermore, the infectious diseases segment is likely to register considerable growth rate over the coming years, as a result of extensive rise in the world’s ageing population and increasing patent’s susceptibility to infectious diseases mainly in the Asian nations like China, Japan, and India.
Hospitals & Clinical Laboratories Segment Held the Largest Market Share in 2022
The hospitals & clinical laboratories segment led the industry and accounted for significant market share in terms of revenue, which is mainly accelerated to the presence of highly improved and enhanced diagnostic infrastructure and healthcare insurance policies. Additionally, highly targeted population of the hospital-preferred patients mainly in the developing countries, growing number of hospital procedures, extensively increasing emphasis of early detection and effective treatment of diseases in hospitals is expected to have positive impact on segment market.
In addition, the biopharmaceutical companies & CROs are projected to account for highest CAGR during the forecast period owing to the rapid surge in the acceptance & demand for the bio-pharmaceuticals to treat un-treatable diseases effectively. Such product to address several previously un-treatable conditions has paved way for innovative drugs in the market.
The North America Region Dominated the Global Market in 2022
North America region dominated the global market with a holding of maximum market revenue. The growth of the regional market is mainly driven by extensive research carried out by various research institutes collaboratively with the many pharmaceutical giants across the region. In addition, rapid infrastructural development and heavily investing in R&D by governments in countries like US and Canada along with the growing demand for novel therapeutic drugs are likely to fuel the adoption and growth of the market in the region.
For instance, in April 2022, LabCorp entered a collaboration with the Xcell Biosciences, with an aim to improve and enhance the critical laboratory work while focusing on the cell & gene therapies. With this agreement, LabCorp will significantly strengthen its comprehensive suite of CGT capabilities and further supporting several biotechnology and pharmaceutical companies.
Asia Pacific region is projected to be the fastest growing region during the anticipated period on account of increased funding on vaccines research and changing disease profiles along with the increasing non-communicable diseases, as a result of high population burden and lack of awareness for advanced testing technologies. Additionally, increased demand for various innovative genotyping products from pharmaceutical companies and development in healthcare infrastructure in countries like India and Indonesia is driving market growth.
Competitive Insight
Some of the major players operating in the global market include Oxford Immunotec, Cellular Technology Ltd., Mabtech, Becton Dickson and Company, and Abcam plc, Mikrogen Diagnostik, Medix Biochemica, Merck KGaA, Anogen-Yes Biotech Laboratories Ltd., Tokyo Chemical Industry Co. Ltd., BOC Sciences, STEMCELL Technologies Inc., SERVA Electrophoresis GmbH, and IST Scitific Ltd.
Recent Developments
- In March 2021, PerkinElmer, announced about the completion of its acquisition of Oxford Immunotec, for a total purchase consideration of USD 590.9 Mn. With this acquisition, the company is likely to leverage its automation capabilities and bring tuberculosis testing to a wider range of customers with easy access.
- Furthermore, in April 2021, Ardigen & ImmuMap, have jointly launched a new research collaboration to focus on the identification and discovery of T-cell receptors reactive towards the recently identified neoantigens of solid tumor patients. Under this collaboration, ELISpot assays, next-generation sequencing, and MHC multimer labeling and sorting will be effectively carried out.
ELISpot and FluoroSpot Assay Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2024 |
USD 305.99 million |
|
Revenue forecast in 2032 |
USD 510.61 million |
|
CAGR |
6.6% from 2024 – 2032 |
|
Base year |
2023 |
|
Historical data |
2019 – 2022 |
|
Forecast period |
2024 – 2032 |
|
Quantitative units |
Revenue in USD million and CAGR from 2024 to 2032 |
|
Segments covered |
By Product, By Application, By End-Use, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
|
Key companies |
Oxford Immunotec, Cellular Technology Ltd., Mabtech, Becton Dickson and Company, and Abcam plc, Mikrogen Diagnostik, Medix Biochemica, Merck KGaA, Anogen-Yes Biotech Laboratories Ltd., Tokyo Chemical Industry Co. Ltd., BOC Sciences, STEMCELL Technologies Inc., SERVA Electrophoresis GmbH, and IST Scitific Ltd. |
FAQ's
The global ELISpot and FluoroSpot assay market size is expected to reach USD 510.61 million by 2032.
Key players in the elispot and fluorospot assay market are Oxford Immunotec, Cellular Technology Ltd., Mabtech, Becton Dickson and Company, and Abcam plc, Mikrogen Diagnostik, Medix Biochemica.
North America contribute notably towards the global elispot and fluorospot assay market.
The global elispot and fluorospot assay market expected to grow at a CAGR of 6.6% during the forecast period.
The elispot and fluorospot assay market report covering key segments are product, application, end-use, and region.
© 2024 Polaris Market Research and Consulting. All rights reserved
